Physician profile
Hannah Smith
NPI 1962155408
$9,506.07
in general payments reported to CMS, 2019-2025
32 companies · $3,076 in 2025
The $3,076 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $2,536 · 2024: $3,769 · 2025: $3,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,090 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,090.14 |
| Education | $290.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,150.22 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,071.01 | 2023-2025 | |
| Dermavant Sciences, INC. | $872.74 | 2023-2024 | Vtama |
| Ucb, INC. | $704.23 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $689.96 | 2023-2025 | Blu-U |
| Incyte Corporation | $664.02 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $632.91 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $594.79 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $350.21 | 2022-2025 | |
| Lilly USA, LLC | $291.53 | 2023-2025 | Olumiant, Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $217.41 | 2023-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $199.85 | 2023-2024 | |
| Leo Pharma INC. | $180.23 | 2022-2025 | Adbry, Anzupgo |
| Mallinckrodt Hospital Products INC. | $106.79 | 2024-2025 | Acthar |
| Arcutis Biotherapeutics, INC. | $105.61 | 2023-2025 | Zoryve |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Pfizer INC. | $96.78 | 2023-2025 | |
| Almirall LLC | $58.91 | 2024-2025 | Klisyri, Seysara |
| Journey Medical Corporation | $55.61 | 2025 | |
| Organon LLC | $49.62 | 2023-2025 | Vtama, Hadlima |
| Kerecis Limited | $45.69 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Amgen INC. | $44.29 | 2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.06 | 2023-2024 | Arazlo, Jublia, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.86 | 2025 | Spevigo |
| Botanix Sb INC | $28.92 | 2025 | Sofdra |
| Boston Scientific Corporation | $24.68 | 2023 | Lithovue |
| Verrica Pharmaceuticals INC. | $20.22 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $17.03 | 2025 | Nemluvio |
| Celltrion USA INC. | $16.72 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $15.46 | 2023 | Idacio |
| Epi Health, LLC | $14.55 | 2022 | |
| Biofrontera INC. | $9.17 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.